Vein closure rates are one of the most frequently cited metrics when evaluating endovenous treatments for varicose veins, but understanding what these numbers actually represent requires looking beyond a single percentage. Closure data is typically reported at multiple follow-up intervals, commonly 12 months and 3 years, because durability over time is a meaningful measure of how well a treated vein remains sealed as opposed to how it looks immediately after the procedure.
What Does a Closure Rate Actually Measure?
A closure rate reflects the percentage of treated veins found, on duplex ultrasound follow-up, to remain fully closed at a given point in time after the procedure. This is distinct from symptom improvement or patient satisfaction, which are measured separately, though the two are often related. Closure is generally assessed by a sonographer or physician looking for absence of blood flow in the treated vein segment, and a vein that has reopened, even partially, is typically classified as a treatment failure for that data point regardless of whether the patient has symptoms.
Why Do 12-Month and 3-Year Figures Sometimes Differ?
It is common and expected for closure rates to decline slightly between earlier and later follow-up points, since some degree of recanalization can occur gradually over time in a small percentage of treated veins. Reporting both a 12-month and a longer-term figure, such as 3 years, gives a more complete picture of durability than a single early measurement would provide. A relatively small difference between these two figures is generally interpreted as reassuring evidence of durability, while a larger drop-off would prompt closer scrutiny of technique or patient selection factors in that particular dataset.
How Should Patients and Clinicians Interpret These Figures?
Closure rate data should always be understood in context, including the specific device or technique studied, the patient population involved, and how closure was defined and measured in that particular report. Figures cited by device manufacturers reflect their own data collection and should be considered manufacturer-reported rather than treated as universal outcomes applicable to every patient or every operator. A qualified physician can help translate these population-level statistics into a realistic expectation for an individual case, taking into account vein diameter, anatomy, and other patient-specific factors.
What Does INVAMED Report for Its Cyanoacrylate System?
As manufacturer-reported data, the VenaBLOCK Non-Thermal Treatment for Vein Disease & Varicose Veins system is cited with a 97% closure rate at 12 months and a 94.6% closure rate at 3 years. These figures illustrate the type of durability tracking discussed above, showing a relatively modest decline between the two follow-up points. As with any manufacturer-reported figure, individual outcomes vary, and these numbers should not be interpreted as a guarantee for any specific patient. Further background on closure technologies is available on the varicose vein products page.
Can closure rates be compared directly between different manufacturers?
Direct comparison is difficult because studies often use different patient populations, follow-up protocols, and definitions of closure. A qualified physician is better positioned to weigh manufacturer-reported figures alongside broader published literature when discussing options with a patient.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.